Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composition for improving ovarian function and application thereof

A technology of ovarian function and composition, applied in the field of stem cells, can solve the problems of repeated illnesses, failure to fundamentally solve the problems of ovarian damage, psychological and physical distress of patients, etc., and achieve the effect of improving ovarian function

Pending Publication Date: 2021-03-30
中科细胞科技(广州)有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For this disease, hormones are often taken orally or injected to help the ovaries recover ovulation function in a short period of time, which does not fundamentally solve the problem of ovarian damage, and cannot achieve a complete cure. psychological and physical distress

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for improving ovarian function and application thereof
  • Composition for improving ovarian function and application thereof
  • Composition for improving ovarian function and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Isolation and culture of umbilical cord mesenchymal stem cells

[0033] 1. Experimental method

[0034] A newborn umbilical cord with a length of 15-20 cm was taken, and the obstetrics and gynecology department required healthy full-term cesarean section fetuses. The tests of HBV antigen, anti-HCV antibody, anti-HIV antibody, anti-Treponema pallidum antibody, mycoplasma, and anti-CMV antibody were all negative.

[0035] Treat within 6 hours, wash with PBS under sterile conditions until there is no blood, cut it longitudinally, remove the blood vessels and cut it into pieces of tissue with a size of 1mm×1mm×1mm, add 0.5ml of umbilical cord tissue suspension to 75cm 2 Add 10ml serum-free complete medium to the culture flask at the same time, put it in 37℃, 5%CO 2 cultured in an incubator. Change the medium in half on the 3rd day and the full volume on the 7th day. Observe under an inverted microscope. When the cells grow to 80% confluent, digest with 0.05% try...

Embodiment 2

[0039] Embodiment 2 Separation of cord blood CGF

[0040] 1. Experimental method

[0041] Using a sodium heparin anticoagulant negative pressure tube, extract cord blood and centrifuge it through a variable speed centrifuge system to obtain PPP (platelet-poor plasma) in the upper layer, liquid CGF (platelet-rich plasma) in the middle and RBC (red blood cells) in the bottom layer, and insert the needle of the syringe On the top of the RBC layer, extract liquid CGF to obtain CGF. The specific method is:

[0042] 1. Take a 10ml blood collection tube containing heparin sodium to collect 10ml of umbilical cord blood, mix it upside down, balance it, and centrifuge at 200g for 10min at room temperature (adjust speed up 1, speed down 1).

[0043] 2. After centrifugation, insert the needle that comes with the 5ml syringe through the cap of the blood collection tube (for exhaust), then connect the 5ml syringe with the long needle, connect the 5ml syringe with the long needle, and then...

Embodiment 3

[0051] Example 3 Combination of Umbilical Cord Mesenchymal Stem Cells and Umbilical Cord Blood CGF

[0052] 1. Experimental method

[0053] 1. Establishment of premature ovarian failure model in rats

[0054] 60 female Wistar rats were adaptively fed in the animal room for 1 week before modeling. Divided into 4 groups randomly according to body weight with digital table method, 15 rats in each group, namely: normal control group (group A), premature ovarian failure (POF) model control group (group B), UMSCs group (group C), UMSCs group +CGF group (Group D).

[0055] Group A was injected with an equal volume of DMSO and 0.9% (mass fraction) sodium chloride injection respectively. At 8:00 every day, gently take a smear of vaginal secretions with a cotton swab, and perform Papanicolaou staining to observe the changes of vaginal exfoliated cells. When continuous estrus is observed for 10 consecutive days Interval, considered successful POI modeling, as group B.

[0056] 2. Com...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition for improving ovarian function. The composition comprises umbilical cord mesenchymal stem cells and umbilical cord blood CGF. The functions of stem cells and CGFare maximized through an ovary multi-site injection administration mode, so that the ovary weight, the follicle number of each stage and the E2 level of an ovarian premature senility model rat are increased, the FSH level and the ovarian granulocyte apoptosis rate are reduced, the Bax protein is remarkably reduced, and the Bcl2 protein is increased. The invention provides a powerful tool for clinically treating the premature ovarian failure and improving the ovarian function.

Description

technical field [0001] The invention relates to the technical field of stem cells, more specifically, to a composition for improving ovarian function and its application. Background technique [0002] Premature ovarian failure is an endocrine disease of the reproductive system caused by ovarian function decline, which is characterized by a decrease in serum estrogen levels and an increase in gonadotropin levels, and it mostly occurs in women after menarche to before the age of 40. In recent years, the incidence rate of premature ovarian failure is increasing year by year, and the incidence rates are 0.1% and 1-3% in 15-29 years old and 30-40 years old respectively, which affects the physical and mental health of patients to varying degrees. The specific manifestations are some symptoms of ovarian function decline, such as menstrual cycle disorder, abnormal menstrual flow, reproductive tract inflammation, and a series of menopausal symptoms, such as skin relaxation, insomnia,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/51A61K35/28A61P15/08
CPCA61K35/28A61K35/51A61P15/08A61K2300/00
Inventor 唐忆琳陈巧林
Owner 中科细胞科技(广州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com